CEO Executive AssistantA pharmaceutical product launch is the moment an organization’s entire pipeline investment either pays off or reveals its gaps. For the pharma CEO, launch is not a marketing event – it is a comprehensive operational test of the company’s cross-functional systems, commercial infrastructure, and execution discipline.
The difference between a successful launch and a disappointing one often has less to do with the quality of the molecule than with the quality of the operating model built to commercialize it. This guide examines how pharma CEOs structure the operational infrastructure required for commercial launch readiness, from market access and sales force build-out to launch metrics and post-launch performance management.
The CEO’s Strategic Role in Launch Operations
Launch decisions touch every function in a pharmaceutical organization: regulatory, medical affairs, market access, commercial, manufacturing, legal, and finance. The CEO’s job is not to make every tactical decision but to ensure that the cross-functional operating model works – that accountabilities are clear, that handoffs happen on time, and that critical decisions are escalated and resolved with sufficient lead time to affect outcomes.
This requires the CEO to establish a launch governance structure early, ideally 18 to 24 months before the anticipated approval date. The governance structure should include a launch steering committee with executive-level membership, a cross-functional launch team with a dedicated launch leader, defined workstream leads for each functional area, and a formal cadence of launch readiness reviews.
According to McKinsey research on pharmaceutical launches, companies that establish robust pre-launch operational infrastructure consistently outperform those that treat launch as a late-stage commercial activity. The operational runway matters enormously.
Market Access: The Foundation of Commercial Success
Market access is frequently the make-or-break element of a pharmaceutical launch, and it is consistently underprepared. CEOs who treat market access as a commercial support function rather than a strategic priority tend to discover the consequences after launch, when payer coverage is narrower than forecast and patient access is constrained.
Effective market access operations begin with a comprehensive payer landscape analysis conducted at least 24 months before launch. This analysis should map:
- Formulary tier placement probability across commercial, Medicare Part D, and Medicaid payer types
- Prior authorization and step therapy barriers likely to be imposed
- Net price expectations after rebates and contracting, segmented by payer type
- Competitive payer positioning for existing treatments in the category
From this analysis, the CEO and commercial leadership should develop a market access strategy that includes: the pricing and contracting strategy, the value dossier that will support payer negotiations, the patient assistance and co-pay support programs designed to bridge coverage gaps, and the HEOR (health economics and outcomes research) evidence generation plan to support formulary arguments.
Market access teams need adequate lead time to build relationships with payer medical directors and pharmacy directors before approval. Cold outreach at the time of FDA approval is too late. The CEO should ensure that the market access team has both the staffing and the budget to build these relationships during the pre-launch window.
Sales Force Infrastructure: Building Before You Need It
The sales force is the most visible element of a pharmaceutical commercial launch, and it is also one of the most complex operational builds. Recruiting, training, and deploying a field force of any size requires a minimum of 9 to 12 months from the first hire to full deployment readiness.
Sales Force Sizing and Structure
Sales force sizing decisions are among the most consequential a CEO makes in advance of launch. Under-size the force and you leave prescriber coverage gaps that competitors exploit. Over-size and you carry fixed costs that damage profitability if launch performance is below forecast.
Size the force from the bottom up, starting with the universe of target prescribers, the desired call frequency per prescriber tier, and the realistic number of quality calls a representative can make per day. Layer in geography, account complexity, and specialty alignment to determine the required headcount. Build in a capacity buffer of 10 to 15 percent for attrition and vacancy lag.
Structure decisions – whether to use a dedicated employee field force, a contract sales organization (CSO), or a hybrid – depend on organizational scale, launch risk profile, and the CEO’s appetite for fixed versus variable cost. First-time launchers often benefit from a CSO partnership that can be scaled up or down more rapidly than a fully employed force.
Training and Launch Readiness Certification
Every field representative must complete a rigorous training curriculum before they call on any physician. This is not merely a legal requirement; it is a quality standard. A representative who cannot fluently discuss the clinical data, safety profile, and differentiated value of the product is a liability in every interaction.
Launch training programs typically include:
- Disease state and mechanism of action education
- Clinical trial data deep-dive, including subgroup analyses relevant to key prescriber segments
- Competitive landscape training
- Reimbursement and market access basics, including how to handle prior authorization questions
- Selling skills and message frameworks
- Compliance and legal requirements (OPDP regulations, Sunshine Act obligations)
- CRM and sales technology proficiency
Certify each representative before deployment. Build a launch readiness dashboard that tracks training completion by representative, region, and district so the CEO can see gaps before launch day.
Launch Metrics: What to Track and When
CEOs who wait for quarterly commercial reviews to understand launch performance are already behind. Launch requires a different cadence – weekly data review in the first 90 days, with a scorecard that captures leading indicators rather than only lagging ones.
A comprehensive launch metrics framework should include:
Early Demand Indicators (Weeks 1 to 8)
- Total prescriptions (TRx) and new-to-brand prescriptions (NBRx) by week
- NBRx by specialty, geography, and target tier
- Share of voice vs. competitive activity (if measurable)
- Patient assistance and co-pay card utilization rates
Market Access Indicators (Months 1 to 3)
- Commercial formulary wins (favorable tier placement) vs. target
- Medicaid formulary status by state
- Medicare Part D coverage breadth
- Prior authorization denial rate and appeal success rate
Sales Force Indicators (Ongoing)
- Call activity vs. plan by district and region
- Message pull-through rates from field coaching assessments
- Target physician reach and frequency vs. plan
- Vacancy rate and time-to-fill for open territories
Financial Indicators
- Gross-to-net percentage by channel (deviation from forecast signals contracting or mix issues)
- Revenue vs. plan, segmented by payer and geography
- Cost per prescription at current volume (tracks unit economics)
Build these metrics into a weekly launch command center meeting attended by commercial, market access, medical affairs, and finance leadership. The CEO should chair or actively participate in this meeting during the first six months post-launch.
Medical Affairs and Commercial Alignment
One of the most common operational failure modes in pharmaceutical launches is poor coordination between medical affairs and commercial functions. Medical affairs is responsible for scientific exchange with key opinion leaders (KOLs), health care provider education, and evidence generation activities. Commercial is responsible for promotional activities with prescribers. The boundary between these activities is legally significant and operationally complex.
The CEO must ensure that medical affairs and commercial are aligned on launch strategy without crossing into inappropriate coordination that could constitute off-label promotion. This requires:
- Clear documented policies distinguishing permissible scientific exchange from promotional activities
- Separate reporting structures with defined escalation paths for boundary questions
- Regular cross-functional alignment meetings with legal and compliance present
- Robust training for both organizations on the relevant regulatory framework
Manufacturing and Supply Chain Readiness
A launch constrained by supply is a dual catastrophe: you lose revenue and you damage prescriber and patient confidence at the moment you most need to build it. CEOs must ensure that supply chain and manufacturing functions are explicitly included in launch governance and that supply readiness criteria are part of the formal launch go/no-go decision.
Key supply readiness requirements include:
- FDA approval of manufacturing site(s) and release of launch inventory
- Wholesale distributor agreements executed and systems tested
- Specialty pharmacy network agreements in place (if applicable)
- Patient support program pharmacy operations tested end-to-end
- Serialization and track-and-trace compliance validated
- Safety stock targets defined and inventories confirmed
Scenario plan your supply chain for both above-forecast and below-forecast demand. Understand your lead times for scaling production, and have a communication plan ready for any supply interruption that might occur during the launch window.
Post-Launch Performance Management
Launch is not an event – it is a multi-year process of building market position, expanding access, and managing the competitive response. The operational systems built for launch must transition into sustainable commercial operations.
At the 90-day mark, conduct a formal launch performance review that compares actual results against pre-launch forecast assumptions. For every assumption that is materially off track, diagnose the root cause and identify operational adjustments. Are NBRx numbers behind because of coverage gaps, prescriber awareness gaps, or representative call quality? Each cause has a different operational response.
Revisit the pharma operations framework to ensure your ongoing commercial operations are fully integrated with your launch learnings. For deeper context on managing the broader pharma operating model, the pharma ops guide provides a comprehensive reference.
Conclusion
A pharmaceutical commercial launch is an operational marathon disguised as a starting gun. The CEOs who execute launches successfully are those who begin building the operational infrastructure years in advance, maintain rigorous cross-functional governance through the launch window, track the right leading indicators with the right cadence, and adapt quickly when assumptions prove wrong.
The molecule got you to the starting line. The operating model determines how far you run from there. Build it with the same rigor you applied to the science, and your launch will be the commercial validation your pipeline investment deserves.
Related Reading
For further context, explore Pharma CEO Business Operations Checklist and Allergy Portfolio Pharma CEO Business Operations: Strategic Execution Guide.